| Literature DB >> 31509986 |
Joana P Costa1, M Joana F Pinheiro1,2, Sílvia A Sousa2, Ana M Botelho do Rego3, Fernanda Marques4, M Conceição Oliveira1, Jorge H Leitão5, Nuno P Mira6, M Fernanda N N Carvalho7.
Abstract
Hydroxide [Ag(OH)L] (L = IVL, VL, VIL, VIIL), oxide [{AgL}2}(μ-O)] (L = IL, IIL, IIIL, VL, VIL) or chloride [AgIIL]Cl, [Ag(VIL)2]Cl complexes were obtained from reactions of mono- or bicamphorimine derivatives with Ag(OAc) or AgCl. The new complexes were characterized by spectroscopic (NMR, FTIR) and elemental analysis. X-ray photoelectron spectroscopy (XPS), ESI mass spectra and conductivity measurements were undertaken to corroborate formulations. The antimicrobial activity of complexes and some ligands were evaluated towards Candida albicans and Candida glabrata, and strains of the bacterial species Escherichia coli, Burkholderia contaminans, Pseudomonas aeruginosa and Staphylococcus aureus based on the Minimum Inhibitory Concentrations (MIC). Complexes displayed very high activity against the Candida species studied with the lowest MIC values (3.9 µg/mL) being observed for complexes 9 and 10A against C. albicans. A significant feature of these redesigned complexes is their ability to sensitize C. albicans, a trait that was not found for the previously investigated [Ag(NO3)L] complexes. The MIC values of the complexes towards bacteria were in the range of those of [Ag(NO3)L] and well above those of the precursors Ag(OAc) or AgCl. The activity of the complexes towards normal fibroblasts V79 was evaluated by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Results showed that the complexes have a significant cytotoxicity.Entities:
Keywords: anti-Candida activity; antibacterials; antifungals; camphorimine; silver complexes
Year: 2019 PMID: 31509986 PMCID: PMC6783962 DOI: 10.3390/antibiotics8030144
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Scheme 1Silver species in aqueous solutions of AgOAc.
Figure 1Camphor derivatives used as ligands: (a) camphorimine and (b) bicamphor type.
Scheme 2Types of complexes obtained from ligands IL–VIL (see Table 1 and Table 2 for details).
Complexes obtained from reaction of Ag(OAc) with camphor ligands (L).
| COMPLEX | LIGAND (L) | IR (cm−1) a | 13C NMR (δ ppm) | ||||
|---|---|---|---|---|---|---|---|
| Y | Z | νC=O | νC=N | C=O | C=N | ||
| [{AgIL}2(µ-O)] | IL ( | NHCOOMe | 1722 | 1649 | (b) | ||
| [{Ag(IIL)}2(µ-O)] | IIL ( | C6H5 | 1745 | 1652 | 207.4 | 173.3 c | |
| [{Ag(IIIL)}2(µ-O)] | IIIL ( | 4-CH3C6H4 | 1747 | 1653 | 206.8 | 171.9 d | |
| [Ag(OH)(IVL´)] e | IVL ( | 4-NH2C6H4 | 1733 | 1642 f | 207.8 | 169.1 c | |
| [{Ag(OH)}(VL)] | VL ( | 4-C6H4 | 1754 | 1685 | 207.3 | 173.2 c | |
| [{Ag(OH)}3(VIL)2] | VIL ( | 3-C6H4 | 1751 | 1668 | 206.6 | 173.0 g | |
| [Ag(OH)(VIIL)] | VIIL ( | 4-(C6H4)2 | 1745 | 1660 | 206.7 | 172.5 g | |
a In KBr pellets. b Not soluble enough. c In CD3CN. d In MeOH-d4. e IVL´ = IVL·CH3COOH. f ν (O=CO), 1593, 1567 cm−1. g In CD2Cl2.
Figure 2XPS regions Ag 3d, N 1s, C 1s and O 1s for complex 1.
Figure 3ESI (+) mass spectrum of a solution of [Ag(VIL)2]Cl (10) in acetonitrile. The insert shows the theoretical isotopic pattern of the cation [Ag(VIL)2]+ i.e., [Ag(C26H32N2O2)2]+.
Complexes obtained from reaction of silver chloride with camphor ligands (L).
| COMPLEX | LIGAND (L) | IR (cm−1) | 13C NMR (δ ppm) | ||||
|---|---|---|---|---|---|---|---|
| Y | Z | νC=O | νC=N | C=O | C=N | ||
| [Ag(IIL)]Cl | IIL ( | C6H5 | 1744 | 1651 | 207.5 | 173.2 a | |
| [{Ag(IIIL)}2(µ-O)] | IIIL ( | 4-CH3C6H4 | 1747 | 1654 | 206.8 | 171.9 b | |
| [{Ag(NH3)}2(μ-VL)(μ-O)] | VL ( | 4-C6H4 | 1744 | 1651 | 207.5 | 173.2 b | |
| [Ag(VIL)2]Cl | VIL ( | 3-C6H4 | 1750 | 1661 | 207.2 | 173.8 a | |
| [Ag2(μ-VIL)(µ-O)] | VIL ( | 3-C6H4 | 1749 | 1660 | 207.3 | 173.9 a | |
a In CD3CN. b In CD2Cl2; From reactions of AgCl with ligands IL and IVL (Figure 1) no complexes could be obtained. In the case of IVL, the hydrated ligand was recovered (IVL·H2O) from solution.
Biological values assessed for the camphorimine silver complexes.
| Complex. | MIC50 (µg/mL) | MIC (µg/mL) | IC50 a (µg/mL) | ||||
|---|---|---|---|---|---|---|---|
|
|
| V79 Cells | |||||
|
| 7.8 ± 0.1 | 15.6 ± 0.1 | 59.4 ± 0.3 | 47 ± 7 | 19 ± 3 | 125 | 7 ± 5 |
|
| 31.3 ± 0.1 | 31.3 ± 0.1 | 56 ± 5 | 78 ± 2 | 43 ± 11 | 58 ± 2 | 8 ± 5 |
|
| 7.8 ± 0.1 | 15.6 ± 0.1 | 125 | 125 | 60 ± 7 | 125 | 3 ± 1 |
|
| 15.6 ± 0.1 | 15.6 ± 0.1 | 54 ± 3 | >125 | 61 ± 4 | >125 | 12 ± 5 |
|
| 125 ± 1 | 250 ± 1 | 250 | >250 | 112± 14 | 250 | 25 ± 14 |
|
| 3.9 ± 0.4 | 7.8 ± 0.1 | 32 ± 1 | 125 | 19 ± 3 | 125 | 2 ± 1 |
|
| - | - | >250 | >250 | >250 | >250 | - |
|
| 3.9 ± 0.1 | 15.6 ± 0.1 | 52.2 ± 0.2 | 23 ± 3 | 43 ± 10 | 125 | 1.7 ± 0.9 |
|
| >500 | >500 | 30.9 ± 0.4 | 12 ± 2 | 16 ± 3 | 29.5 ± 0.1 | 0.6 ± 0.2 |
|
| 500 ± 1 | >500 | 14 ± 2 | 10 ± 1 | 12 ± 1 | 30 ± 2 | >30 |
a IC50 values for 48 h incubation.